Britt Rudnas

Clinicopathological features of mismatch repair-deficient colorectal cancer: an observational experience from Romagna, Italy

Francesco Vasuri, Alessandra Boccaccino, Chiara Zingaretti, Isabella Banchelli et autres

No abstract available.

it (code pays fourni par la source)

A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas

Alberto Bongiovanni, Chiara Liverani, Flavia Foca, Francesca Bergamo et autres

BACKGROUND: Neuroendocrine Carcinomas (NECs) prognosis is poor.No standard second-line therapy is currently recognized after failure of platinum-based first-line treatment. FOLFIRI and CAPTEM regimens have shown promising activity in preliminary studies. We aimed to evaluate these regimens in metastatic NEC patients. METHODS: This …

it (code pays fourni par la source)

Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer

Salvatore Paiella, Gabriele Capurso, Silvia Carrara, Erica Secchettin et autres

INTRODUCTION: Pancreatic cancer (PC) surveillance of high-risk individuals (HRI) is becoming more common worldwide, aiming at anticipating PC diagnosis at a preclinical stage. In 2015, the Italian Registry of Families at Risk of Pancreatic Cancer was created. We aimed to assess the …

it, ca (code pays fourni par la source)

Supplementary Data from Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study

Andrea Casadei Gardini, Giorgia Marisi, Vincenzo Dadduzio, Laura Gramantieri et autres

All Supplementary Data

Supplementary Data from Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study

Andrea Casadei Gardini, Giorgia Marisi, Vincenzo Dadduzio, Laura Gramantieri et autres

All Supplementary Data

Data from Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study

Andrea Casadei Gardini, Giorgia Marisi, Vincenzo Dadduzio, Laura Gramantieri et autres

AbstractPurpose: After 10 years of clinical practice and research studies, there are still no validated prognostic or predictive factors of response to sorafenib for hepatocellular carcinoma (HCC). On the basis of the results of our two retrospective studies, we designed the multicenter …

Data from Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study

Andrea Casadei Gardini, Giorgia Marisi, Vincenzo Dadduzio, Laura Gramantieri et autres

AbstractPurpose: After 10 years of clinical practice and research studies, there are still no validated prognostic or predictive factors of response to sorafenib for hepatocellular carcinoma (HCC). On the basis of the results of our two retrospective studies, we designed the multicenter …

Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey

Michele Reni, M. Reni, E Giommoni, F C Bergamo et autres

BACKGROUND: Information about the adherence to scientific societies guidelines in the 'real-world' therapeutic management of oncological patients are lacking. This multicenter, prospective survey was aimed to improve the knowledge relative to 2017-2018 recommendations of the Italian Association of Medical Oncology (AIOM). PATIENTS …

it (code pays fourni par la source)

Adjuvant chemotherapy after neoadjuvant chemo-radiotherapy and surgery in locally advanced rectal cancer. A systematic review of literature with a meta-analysis of randomized clinical trials

Emiliano Tamburini, Davide Tassinari, Matteo Ramundo, Alfonso De Stefano et autres

it (code pays fourni par la source)

Clinical research activities during COVID-19: the point of view of a promoter of academic clinical trials

Linda Valmorri, Bernadette Vertogen, Chiara Zingaretti, Anna Miserocchi et autres

BACKGROUND: During the COVID-19 emergency, IRST IRCCS, an Italian cancer research institute and promoter of no profit clinical studies, adapted its activities and procedures as per European and national guidelines to maintain a high standard of clinical trials, uphold participant safety and …

it (code pays fourni par la source)

How Many Cancer Clinical Trials Can a Clinical Research Coordinator Manage? The Clinical Research Coordinator Workload Assessment Tool

Francesca Fabbri, Giorgia Gentili, Patrizia Serra, Bernadette Vertogen et autres

PURPOSE: Cancer clinical trials (CTs) are now more complex than ever before and require dedicated personnel (clinical research coordinators [CRCs]) to perform regulatory and administrative activities and protocol- and patient-related procedures. We developed a simple tool to measure the workload (WL) of …

it (code pays fourni par la source)

Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study

Andrea Casadei Gardini, Giorgia Marisi, Vincenzo Dadduzio, Laura Gramantieri et autres

Abstract Purpose: After 10 years of clinical practice and research studies, there are still no validated prognostic or predictive factors of response to sorafenib for hepatocellular carcinoma (HCC). On the basis of the results of our two retrospective studies, we designed the …

it, us (code pays fourni par la source)